Clinical trials: HNSCC

HNSCC

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

• Terminated
• Age: All ages
• Phase 2
• Results posted

This is a Phase II single-arm window trial to assess the clinical and biological effects of neoadjuvant abemaciclib in patients with HPV-negative head and neck squamous cell carcinoma (HNSCC).

Trial name

NCT04169074

Testing

Abemaciclib

Where

2 sites in United States

Volunteers

7 people

Sponsor

University of Arizona